Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonesitatug vedotin + capecitabine
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sonesitatug vedotin + capecitabine is an investigational combination regimen consisting of sonesitatug vedotin (Sone-Ve, AZD0901), a Claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate (ADC), and capecitabine, an oral fluoropyrimidine chemotherapy prodrug of 5-fluorouracil. Sonesitatug vedotin comprises a humanized anti-CLDN18.2 monoclonal antibody conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable linker. Capecitabine is converted enzymatically to 5-fluorouracil in vivo, where it inhibits thymidylate synthase to block DNA synthesis. This combination is being evaluated in the Phase III CLARITY-Gastric02 trial (NCT07431281) as a first-line treatment for patients with CLDN18.2-positive, HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma, specifically in cohorts who are PD-L1 negative or ineligible for immune checkpoint inhibitors.
- Other names
- AZD0901 + capecitabineCM-G901 + capecitabineCMG901 + capecitabineSone-Ve + capecitabinesonesitatug vedotin and capecitabine
02
Targets
Claudin 18.2TS (Thymidylate synthase)
Beyond the preview
Go deeper on sonesitatug vedotin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonesitatug vedotin + capecitabine.